Merck, Ridgeback Upbeat on Trial for Covid Antiviral Treatment
This article is for subscribers only.
Ridgeback Biotherapeutics LP said it had been encouraged by preliminary data from a Phase 2a trial of its Covid-19 oral antiviral treatment molnupiravir, which it is developing in partnership with Merck & Co.
The results were from Ridgeback’s trial to evaluate the treatment’s safety, tolerability, and efficacy to eliminate SARS-CoV-2, the companies said in a joint statement.